MetaCap

Addex Therapeutics (ADXN) vs Kyntra Bio (KYNB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kyntra Bio is the larger company by market cap ($6.3 million vs $6.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADXN+10.86%KYNB-74.55%
+76%-3%-82%
Oct 7, 20261 yearNov 20, 2026
ADXN+7.81%KYNB-74.47%
+31%-24%-79%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADXN versus KYNB key metrics
MetricADXNKYNB
Share price$3.47$1.56
Market cap$6.08M$6.32M
1-day change+2.06%-13.33%
YTD return—-82.23%
1-year return—-81.47%
5-year return—-99.49%
EPS (TTM)$-7.56$-4.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.44M
Revenue growth (YoY)—-78.26%
Net income (latest FY)—$183.45M
Gross margin—91.37%
Operating margin—-712.66%
Net margin—2848.63%
52-week high$10.43$10.47
52-week low$2.56$1.56
Distance from 52-week high-66.73%-85.10%
Analyst consensus—none
Avg. price target upside—+2442.95%
Average volume383.35K29.96K
Shares outstanding1.75M4.05M
Employees334
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Addex Therapeutics

ADXN stock →

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About Kyntra Bio

KYNB stock →

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

ADXN vs KYNB FAQ

Which is bigger, Addex Therapeutics or Kyntra Bio?

Kyntra Bio (KYNB) is larger, with a market capitalization of $6.32M compared with $6.08M for Addex Therapeutics (ADXN).

Are Addex Therapeutics and Kyntra Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons